Bacteriophage therapies for Gram-negative respiratory infections
| Phage components | Bacterial target | Development phase | Administration route | |
| AB-PA01 cocktail | Pa193, Pa204, Pa222, Pa223 | P. aeruginosa | Pre-clinical | Intravenous ± nebulised |
| AB-PA01 m1 | Pa193, Pa204, Pa222, Pa223, Pa176 | P. aeruginosa | Pre-clinical | Intravenous ± nebulised |
| Acinetobacter therapies | 2ϕ ± ϕAb124 | A. baumannii | Pre-clinical | Topical or nebulised |
| Achromobacter cocktail | Not specified | A. xylosoxidans | Pre-clinical | Oral + nebulised |
| Navy Phage cocktail 1 | Paϕ1, PaSKWϕ17, PaSKWϕ22 | P. aeruginosa | Pre-clinical | Intravenous ± nebulised |
| Navy Phage cocktail 2 | PaATFϕ1 and PaATFϕ3 | P. aeruginosa | Pre-clinical | Intravenous |
| Adaptive Therapeutics phage | BdPF16phi4281 | B. dolosa | Pre-clinical | Intravenous |
P. aeruginosa: Pseudomonas aeruginosa; A. baumannii: Acinetobacter baumannii; A. xylosoxidans: Achromobacter xylosoxidans; B. dolosa; Burkholderia dolosa.